Cargando…

A Movement Monitor Based on Magneto-Inertial Sensors for Non-Ambulant Patients with Duchenne Muscular Dystrophy: A Pilot Study in Controlled Environment

Measurement of muscle strength and activity of upper limbs of non-ambulant patients with neuromuscular diseases is a major challenge. ActiMyo(®) is an innovative device that uses magneto-inertial sensors to record angular velocities and linear accelerations that can be used over long periods of time...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le Moing, Anne-Gaëlle, Seferian, Andreea Mihaela, Moraux, Amélie, Annoussamy, Mélanie, Dorveaux, Eric, Gasnier, Erwan, Hogrel, Jean-Yves, Voit, Thomas, Vissière, David, Servais, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896626/ https://www.ncbi.nlm.nih.gov/pubmed/27271157 http://dx.doi.org/10.1371/journal.pone.0156696

Ejemplares similares

Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype
por: Servais, Laurent, et al.
Publicado: (2015)

Upper Limb Strength and Function Changes during a One-Year Follow-Up in Non-Ambulant Patients with Duchenne Muscular Dystrophy: An Observational Multicenter Trial
por: Seferian, Andreea Mihaela, et al.
Publicado: (2015)

Upper Limb Evaluation and One-Year Follow Up of Non-Ambulant Patients with Spinal Muscular Atrophy: An Observational Multicenter Trial
por: Seferian, Andreea Mihaela, et al.
Publicado: (2015)

Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy
por: Lilien, Charlotte, et al.
Publicado: (2021)

Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials
por: Servais, Laurent, et al.
Publicado: (2022)

A Robust Indoor/Outdoor Navigation Filter Fusing Data from Vision and Magneto-Inertial Measurement Unit
por: Caruso, David, et al.
Publicado: (2017)

Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial
por: Flanigan, Kevin M., et al.
Publicado: (2013)

24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy
por: Mazzone, Elena Stacy, et al.
Publicado: (2013)

Preserved thenar muscles in non‐ambulant Duchenne muscular dystrophy patients
por: Naarding, Karin J., et al.
Publicado: (2021)

Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy
por: Zambon, Alberto A., et al.
Publicado: (2022)

Evaluation of Cardiac, Autonomic Functions in Ambulant Patients with Duchenne Muscular Dystrophy
por: Nayak, Amritharekha, et al.
Publicado: (2023)

Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
por: Amor, Fatima, et al.
Publicado: (2021)

Correction: 24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy
por: Mazzone, Elena Stacy, et al.
Publicado: (2013)

Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
por: Mendell, Jerry R., et al.
Publicado: (2016)

MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy
por: Naarding, Karin J., et al.
Publicado: (2020)

The 6 Minute Walk Test and Performance of Upper Limb in Ambulant Duchenne Muscular Dystrophy Boys
por: Pane, Marika, et al.
Publicado: (2014)

Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
por: McDonald, Craig M, et al.
Publicado: (2021)

Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
por: Markati, Theodora, et al.
Publicado: (2021)

miR-379 links glucocorticoid treatment with mitochondrial response in Duchenne muscular dystrophy
por: Sanson, M., et al.
Publicado: (2020)

Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes
por: Pane, Marika, et al.
Publicado: (2014)

Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy
por: Zhang, Shu, et al.
Publicado: (2021)

Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
por: Le Guiner, Caroline, et al.
Publicado: (2017)

Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability?
por: Pane, Marika, et al.
Publicado: (2023)

Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial
por: Servais, Laurent, et al.
Publicado: (2022)

Correction: Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes
por: Pane, Marika, et al.
Publicado: (2015)

Correction: Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes
Publicado: (2015)

Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment
por: Poleur, Margaux, et al.
Publicado: (2021)

Evaluating the Feasibility and Reliability of Remotely Delivering and Scoring the North Star Ambulatory Assessment in Ambulant Patients with Duchenne Muscular Dystrophy
por: Emery, Nicholas, et al.
Publicado: (2022)

Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
por: Ayyar Gupta, Vandana, et al.
Publicado: (2023)

Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
por: Frank, Diane E., et al.
Publicado: (2020)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

Early loss of ambulation is not a representative clinical feature in Duchenne muscular dystrophy dogs: remarks on the article of Barthélémy et al.
por: Duan, Dongsheng, et al.
Publicado: (2015)

Respiratory involvement in ambulant and non-ambulant patients with facioscapulohumeral muscular dystrophy
por: Moreira, Sandra, et al.
Publicado: (2017)

Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy
por: Beckers, Pablo, et al.
Publicado: (2021)

Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy
por: Barthélémy, Inès, et al.
Publicado: (2014)

Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy
por: Mariot, Virginie, et al.
Publicado: (2020)

Letter to the Editor: In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in Boys with Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study, and Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
por: Muntoni, Francesco, et al.
Publicado: (2023)

Semi-Automated Analysis of Diaphragmatic Motion with Dynamic Magnetic Resonance Imaging in Healthy Controls and Non-Ambulant Subjects with Duchenne Muscular Dystrophy
por: Bishop, Courtney A., et al.
Publicado: (2018)

Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy
por: Buyse, Gunnar M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4radce0ol0dsf9vmafkjgb0oad